Sumitomo Dainippon Pharma Co., Ltd v. Par Pharmaceutical, Inc

Court

District Court, S.D. New York (S.D.N.Y.)
Official Court Website →

Assigned judge

Ronnie Abrams · 1,932 cases in index

Docket number

1:18-cv-02107

Nature of suit

835
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal question

Date filed

03/08/2018

Date terminated

04/02/2018

16 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Sumitomo Dainippon Pharma Co., Ltd · 15 cases
• defendant · Par Pharmaceutical, Inc · 137 cases

Part of a Larger Litigation Pattern

This is one of 138 Patent - ANDA cases in our index naming Par Pharmaceutical, Inc — a possible mass-tort or coordinated-litigation cluster.

• Par Pharmaceutical, Inc v. Cipla Limited
  District Court, D. New JerseyFiled 02/28/2023
• Par Pharmaceutical, Inc v. Cipla Limited
  District Court, D. New JerseyFiled 05/13/2022
• Par Pharmaceutical, Inc v. Dr. Reddy'S Laboratories, Inc
  District Court, D. New JerseyFiled 12/07/2020
• Par Pharmaceutical, Inc v. Aurobindo Pharma U.S.A., Inc
  District Court, D. New JerseyFiled 12/07/2020
• Par Pharmaceutical, Inc v. Eagle Pharmaceuticals, Inc
  District Court, D. New JerseyFiled 12/07/2020
• Par Pharmaceutical, Inc v. Amneal Eu, Limited
  District Court, D. New JerseyFiled 12/07/2020

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Sumitomo Dainippon Pharma Co., Ltd v. Par Pharmaceutical, Inc?

Sumitomo Dainippon Pharma Co., Ltd v. Par Pharmaceutical, Inc is a federal patent - anda lawsuit filed on 03/08/2018 in the District Court, S.D. New York. The case was terminated on 04/02/2018. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, S.D. New York, docket number 1:18-cv-02107.

When was the case filed?

Sumitomo Dainippon Pharma Co., Ltd v. Par Pharmaceutical, Inc was filed on 03/08/2018. It was terminated on 04/02/2018.